Buprenorphine
Generic Name: buprenorphine
Brand Names:
Buprenorphine
Buprenorphine sublingual tablets are indicated for the treatment of opioid dependence as part of a comprehensive treatment plan that incorporates counseling and psychosocial support.
Overview
Buprenorphine sublingual tablets are indicated for the treatment of opioid dependence as part of a comprehensive treatment plan that incorporates counseling and psychosocial support.
Uses
Indicated for the treatment of opioid dependence and preferred for induction. Should be used as part of a comprehensive treatment plan including counseling and psychosocial support.
Dosage
Administer sublingually as a single daily dose. Tablets must be taken whole and not cut, chewed, or swallowed. Induction dosing ranges from 2-16 mg daily, with maintenance typically between 4-24 mg daily based on individual response.
Side Effects
Common adverse events include oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema.
Interactions
Significant interactions with benzodiazepines, CNS depressants, CYP3A4 inhibitors/inducers, antiretrovirals, serotonergic drugs, MAOIs, muscle relaxants, diuretics, and anticholinergic medications.
Warnings
Life-threatening respiratory depression and death risk, especially with benzodiazepines. Pediatric exposure dangers. Neonatal withdrawal syndrome. Dental adverse events including tooth loss. Hepatic events. Contraindicated in patients with hypersensitivity to buprenorphine.
Pregnancy
Limited data show no increased risk of major malformations. Neonatal opioid withdrawal syndrome may occur in newborn infants. Buprenorphine passes into breast milk at low levels.
Frequently Asked Questions
What is Buprenorphine used for?▼
Indicated for the treatment of opioid dependence and preferred for induction. Should be used as part of a comprehensive treatment plan including counseling and psychosocial support.
What are the side effects of Buprenorphine?▼
Common adverse events include oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema.
Can I take Buprenorphine during pregnancy?▼
Limited data show no increased risk of major malformations. Neonatal opioid withdrawal syndrome may occur in newborn infants. Buprenorphine passes into breast milk at low levels.
What are the important warnings for Buprenorphine?▼
Life-threatening respiratory depression and death risk, especially with benzodiazepines. Pediatric exposure dangers. Neonatal withdrawal syndrome. Dental adverse events including tooth loss. Hepatic events. Contraindicated in patients with hypersensitivity to buprenorphine.
Related Medications
Octinoxate, Oxybenzone, Homosalate, Octocrylene, Octisalate, Avobenzone
octinoxate, oxybenzone, homosalate, octocrylene, octisalate, avobenzone
Purpose Sunscreen
Lamotrigine Chewable Dispersible
lamotrigine chewable dispersible
Anti-epileptic Agent [EPC]
11. DESCRIPTION Lamotrigine tablets for oral suspension USP (chewable dispersible tablets), an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Lamotrigine’s chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine, its molecular formula is C 9 H 7 N 5 Cl 2 , and its molecular weight is 256.09. Lamotrigine is a white to pale cream-colored powder and has a pK a of 5.7.
Nicotine Polacrilex Lozenge 4 Mg
nicotine polacrilex lozenge 4 mg
Cholinergic Nicotinic Agonist [EPC]
Purpose Stop smoking aid
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.